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Linezolid is a member of oxazolidinons and it inhibits
protein synthesis at the initiation step. In this step,
formation of 70S complex occurs by association of 50S
ribosomal subunit, and 30S initiation complex, which is
made of 30S ribosomal subunit, mRNA, and methionine
carrying tRNA. Linezolid prevents this formation by
binding the 50S subunit (1–3).
Although it is a new agent, resistance has been
reported from several centers worldwide, but it is still
rare. Target modification is the main factor in linezolid
resistance. Mutations in V domain of 23S rRNA, and
ribosomal proteins such as L3 and L4 emerge as resistance
(4,5). Nonmutational oxazolidinon resistance is due to
the chloramphenicol–florfenicol resistance (cfr) gene.
Posttranscriptional methylation of the 23S rRNA at
position A2503 by a methyltransferase encoded by the
cfr gene causes resistance to phenicols, lincosamides,
oxazolidinones, pleuromutilins, and streptogramin A
antibiotics (6,7).
A 61-year-old woman with sarcoidosis was hospitalized
after cardiopulmonary resuscitation (CPR) in the intensive
care unit of a medical center. Methicillin-resistant coagulase
negative staphylococcus (MR-CoNS) was isolated from
blood cultures on days 2 and 9 of hospitalization. After the
first isolation of MR-CoNS, ceftriaxone therapy (2 gr I.V.
once a day) was replaced by linezolid (600 mg I.V. twice a
day) and linezolid was used for 14 days until the patient
was transferred to our center. Two sets of blood culture
samples (1 set from the peripheral vein and 1 set from the
central venous catheter) were sent to our laboratory. Blood
cultures are incubated in a Bactec (Becton Dickinson
Diagnostic Instrument Systems, Sparks, MD, USA)
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instrument. Both blood cultures were signaled positive by
the instrument. VITEK2 Compact reported the growing
organism as Staphylococcus epidermidis and it was
confirmed by 16S rRNA sequencing.
An antibiotic susceptibility test (AST) was performed
by Kirby–Bauer disk diffusion method and minimum
inhibitory concentration (MIC) values were obtained
by E-test. The results were interpreted according to
Clinical and Laboratory Standards Institute (CLSI)
recommendations (7). AST results were also confirmed by
VITEK 2 Compact (bioMerieux, Marcy L’Etoile, France).
In
our
study,
sequencing
primers
5’-AGAGTTTGATCCTGGCTCAG-3’
(0008F)
and
5’-TACCGCGGCTGCTGGCAC-3’ (0532R) were used for
the 16S rRNA gene, and 5-GCGGTCGCCTCCTAAAAG-3
(upper primer) and 5-ATCCCGGTCCTCTCGTACTA-3
(lower primer) were used for the domain V of 23S rRNA
region amplifications as described before (8). Both of the
amplification results were proved by loading products to
1% agarose gel. The bands were determined for 16S and
23S gene regions. Post-PCR purification was applied to
products excised from agarose gel by using a High Pure
PCR Product Purification kit (Roche Diagnostics GmbH,
Mannheim, Germany). The purified samples were used for
sequencing reaction by DYEnamic ET Terminator Cycle
Sequencing Kit (Amersham Biosciences, Piscataway, NJ,
USA). Samples were loaded to ABI PRISM 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
BLAST analysis was applied to the sequencing results.
In the disk diffusion test, we did not observe any
inhibition zone around the linezolid disk, and linezolid
MIC determined by E-test was 256 µg/mL (Figure 1).
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Figure 1. Linezolid E-test and disk diffusion results.

VITEK2 Compact reported a MIC value of ≥8 µg/mL
for linezolid. We also detected reduced susceptibility
for teicoplanin by disk diffusion method, and VITEK2
Compact reported an intermediate susceptibility for
both vancomycin and teicoplanin, whereas the results
of the E-test showed that the isolate was susceptible to
glycopeptides with MIC values of 3 µg/mL and 6 µg/
mL for vancomycin and teicoplanin, respectively. The
isolate was also susceptible to quinupristin/dalfopristin
and daptomycin, and resistant to several antibiotics such
as chloramphenicol, erythromycin, or rifampicin. AST
results were obtained by all 3 methods for these antibiotics.
16S rRNA and 23S rRNA gene regions were amplified and
both of the amplification results were proved by loading
products to 1% agarose gel. The bands we determined for
16S and 23S were between 500 and 550 and 400 and 450
bp, respectively (Figure 2).
The obtained sequence of 23S rRNA was compared
with sequences from susceptible Staphylococcus
epidermidis strain ATCC 12228 (GenBank accession
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Figure 2. Ethidium bromide staining of PCR products.

number NC_004461.1). The isolate had a G to T mutation
at position 2576 (E. coli numbering) and A to G mutation
at position 2309 (E. coli numbering) (Figure 3).
After reporting linezolid resistance, the therapy
was replaced by daptomycin (500 mg I.V. once a day)
and the central venous catheter present was removed.
Staphylococcus epidermidis was not isolated from any
sample including the central venous catheter of our patient
thereafter.
Linezolid is bacteriostatic against staphylococci
and enterococci but shows bactericidal activity against
pneumococci (9). Despite its bacteriostatic effect it can be
used for the treatment of bacteremia and even endocarditis
(9,10).
Linezolid-resistant strains of methicillin-resistant
Staphylococcus spp. are reported. G2576T is the most
common mutation related with linezolid resistance in
staphylococci and enterococci (11). It is also reported
in enterococci in Turkey (12). Furthermore, there are
several mutations reported for staphylococci: G2447T
in Staphylococcus aureus or G2631T and C2534T in
Staphylococcus epidermidis (5). G2576T mutation together
with the cfr gene can also be seen Staphylococcus epidermidis
(13). To the best of our knowledge, no linezolid resistant
MR-CoNS strain has been reported in Turkey (14,15).
In our isolate there is an additional mutation at
position 2309. It is thought that linezolid binds to any
location in the vicinity of the peptidyl transferase center
(PTC) (4). The PTC is located in domain V of 23S rRNA,
and this center plays a key role in peptide bond formation
and peptide release (16). Although PTC is known as the
primer binding site of the drug, it is controversial that
different sites of ribosome can interact with linezolid. The
A-site and P-site of large ribosomal units are among these
interaction regions (17). Nucleotide A2309 is located in
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Figure 3. Detected mutations obtained by BLAST analysis.

helix 84 of 23S rRNA. This nucleotide was identified as a
point of cross-linking from P-site or A-site bound tRNA
(18,19).
Several cross-linking points were detected, and
further studies are needed to demonstrate the relationship
between mutations, especially in these regions, and
linezolid resistance. Prolonged use of linezolid as in our
patient plays an important role in selecting resistant

strains. Precautions such as pervading rational antibiotic
use and establishing infection control measures are crucial
in controlling this emerging problem.
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